Fourteen women with normoprolactinaemic amenorrhoea were treated with bromocriptine (2 . 5 mg twice daily) for a period ranging from 4 to 17 weeks, while a matched group of 19 amenorrhoeic women were treated with a placebo 8one tablet twice daily) for 4 to 12 weeks. About half of the patients in both groups had at least one episode of vaginal bleeding during treatment. There was no clear difference in the menstrual and ovulatory pattern between placebo and bromocriptine groups
AbstractBackground: Among women with unexplained infertility, 28% to 55% of patients with galactorrh...
Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactin...
Background: Menorrhagia (menstrual blood loss more than 80% per cycle) affects 10-33% of women at so...
Thirty-two amenorrheic patients were treated with a tablet oral placebo preparation for a period var...
Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores ...
SUMMARY: To assess the efficacy and possible potential side effects of alternate routes of treatment...
Objective: There are relatively few reports in the world comparing the beneficial and adverse effect...
Background: Dopamine agonists are the preferred treatment for most patients with hyperprolactinemia ...
Hyperprolactinaemia is areal challenge for gynecologist and endocrinologists ,bromocriptine was used...
Objectives: to compare the clinical effectiveness, side effects and tolerability of rectal versus va...
Sixty-eight mothers who did not want to breast-feed their babies were submitted to one of the follow...
Bromocriptine, a dopaminergic agonist, has been used to treat many endocrine disorders. In hyperprol...
Objective: To compare the efficacy of puerperal lactation suppression by metergoline versus bro-mocr...
Fifteen young women with a diagnosis of secondary hypothalamic amenorrhea of at least 2 years' durat...
BackgroundProgestin-only pills are associated with irregular bleeding pattern including amenorrhea. ...
AbstractBackground: Among women with unexplained infertility, 28% to 55% of patients with galactorrh...
Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactin...
Background: Menorrhagia (menstrual blood loss more than 80% per cycle) affects 10-33% of women at so...
Thirty-two amenorrheic patients were treated with a tablet oral placebo preparation for a period var...
Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores ...
SUMMARY: To assess the efficacy and possible potential side effects of alternate routes of treatment...
Objective: There are relatively few reports in the world comparing the beneficial and adverse effect...
Background: Dopamine agonists are the preferred treatment for most patients with hyperprolactinemia ...
Hyperprolactinaemia is areal challenge for gynecologist and endocrinologists ,bromocriptine was used...
Objectives: to compare the clinical effectiveness, side effects and tolerability of rectal versus va...
Sixty-eight mothers who did not want to breast-feed their babies were submitted to one of the follow...
Bromocriptine, a dopaminergic agonist, has been used to treat many endocrine disorders. In hyperprol...
Objective: To compare the efficacy of puerperal lactation suppression by metergoline versus bro-mocr...
Fifteen young women with a diagnosis of secondary hypothalamic amenorrhea of at least 2 years' durat...
BackgroundProgestin-only pills are associated with irregular bleeding pattern including amenorrhea. ...
AbstractBackground: Among women with unexplained infertility, 28% to 55% of patients with galactorrh...
Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactin...
Background: Menorrhagia (menstrual blood loss more than 80% per cycle) affects 10-33% of women at so...